46 Recruiting Studies Using Blinatumomab
Active clinical trials that use this intervention, sourced directly from the NIH registry.
Browse by conditionTrials Using Blinatumomab
A Study to Investigate Blinatumomab in Combination With Chemotherapy in Patients With Newly Diagnosed B-Lymphoblastic Leukemia
π Children's Hospital of Alabama β Birmingham, Alabama
B Acute Lymphoblastic Leukemia
View Study & Checklist βCombination Chemotherapy With or Without Blinatumomab in Treating Patients With Newly Diagnosed BCR-ABL-Negative B Lineage Acute Lymphoblastic Leukemia
π University of Alabama at Birmingham Cancer Center β Birmingham, Alabama
Acute Lymphoblastic Leukemia
View Study & Checklist βTesting the Use of Steroids and Tyrosine Kinase Inhibitors With Blinatumomab or Chemotherapy for Newly Diagnosed BCR-ABL-Positive Acute Lymphoblastic Leukemia in Adults
π University of Alabama at Birmingham Cancer Center β Birmingham, Alabama
B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1
View Study & Checklist βBlinatumomab and Tyrosine Kinase Inhibitor Therapy in People With Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia
π Mount Sinai Hospital β New York, New York
Acute Lymphoblastic Leukemia
View Study & Checklist βTCRΞ±Ξ²-depleted Progenitor Cell Graft With Additional Memory T-cell DLI, Plus Selected Use of Blinatumomab, in Naive T-cell Depleted Haploidentical Donor Hematopoietc Cell Transplantation for Hematologic Malignancies
π St. Jude Children's Research Hospital β Memphis, Tennessee
Acute Lymphoblastic Leukemia (ALL)
View Study & Checklist βBlinatumomab and Combination Chemotherapy or Dasatinib, Prednisone, and Blinatumomab in Treating Older Patients With Acute Lymphoblastic Leukemia
π University of Alabama at Birmingham Cancer Center β Birmingham, Alabama
Acute Lymphoblastic Leukemia
View Study & Checklist βA Study of Subcutaneous Blinatumomab in Children With R/R and and MRD+ B-Cell Precursor Acute Lymphoblastic Leukemia
π Lucile Packard Childrens Hospital Stanford β Palo Alto, California
Relapsed/Refractory B-Cell Precursor Acute Lymphoblastic Leukemia
View Study & Checklist βLow-Intensity Chemotherapy, Ponatinib and Blinatumomab in Treating Patients With Philadelphia Chromosome-Positive and/or BCR-ABL Positive Acute Lymphoblastic Leukemia
π M D Anderson Cancer Center β Houston, Texas
Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive
View Study & Checklist βA Phase 1b/2 Study to Assess the Safety and Efficacy of Subcutaneous Blinatumomab in Combination With Low Intensity Chemotherapy in Older Patients With Newly Diagnosed B-Cell Acute Lymphoblastic Leukemia
π The University of Texas M. D. Anderson Cancer Center β Houston, Texas
B-cell Acute Lymphoblastic Leukemia
View Study & Checklist βBlinatumomab in Treating Younger Patients With Relapsed B-cell Acute Lymphoblastic Leukemia
π Children's Hospital of Alabama β Birmingham, Alabama
Recurrent B Acute Lymphoblastic Leukemia
View Study & Checklist βA Study of Blinatumomab in Patients With Pre B-cell ALL and B-cell NHL as Post-allo-HSCT Remission Maintenance
π Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins β Baltimore, Maryland
Acute Lymphoblastic Leukemia
View Study & Checklist βProvision of TCRΞ³Ξ΄ T Cells and Memory T Cells Plus Selected Use of Blinatumomab in NaΓ―ve T-cell Depleted Haploidentical Donor Hematopoietic Cell Transplantation for Hematologic Malignancies Relapsed or Refractory Despite Prior Transplantation
π St. Jude Children's Research Hospital β Memphis, Tennessee
Acute Lymphoblastic Leukemia (ALL)
View Study & Checklist βTotal Therapy XVII for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia and Lymphoma
π Lucile Packard Children's Hospital Stanford University β Palo Alto, California
Acute Lymphoblastic Leukemia
View Study & Checklist βPembrolizumab and Blinatumomab in Treating Participants With Recurrent or Refractory Acute Lymphoblastic Leukemia
π City of Hope Medical Center β Duarte, California
CD19 Positive
View Study & Checklist βVenetoclax, Dasatinib, Prednisone, Rituximab and Blinatumomab for the Treatment of Newly Diagnosed or Relapsed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia or Mixed Phenotype Acute Leukemia
π OHSU Knight Cancer Institute β Portland, Oregon
B Acute Lymphoblastic Leukemia
View Study & Checklist βTrial Treating Relapsed Acute Lymphoblastic Leukemia With Venetoclax and Navitoclax
π Memorial Sloan Kettering Cancer Center β New York, New York
Refractory Acute Lymphoblastic Leukemia
View Study & Checklist βBlinatumomab and Nivolumab With or Without Ipilimumab in Treating Patients With Poor-Risk Relapsed or Refractory CD19+ Precursor B-Lymphoblastic Leukemia
π Yale University β New Haven, Connecticut
Recurrent B Acute Lymphoblastic Leukemia
View Study & Checklist βStudy Comparing Blinatumomab Alternating With Low-intensity Chemotherapy Versus Standard of Care Chemotherapy for Older Adults With Newly Diagnosed Philadelphia-negative B-cell Precursor Acute Lymphoblastic Leukemia
π City of Hope National Medical Center β Duarte, California
Newly Diagnosed Philadelphia (Ph)-Negative B-cell Precursor Acute Lymphoblastic Leukemia (ALL)
View Study & Checklist βA Study of Subcutaneous Blinatumomab Administration in Participants With R/R and MRD+ B-ALL
π University of California San Francisco Fresno at Community Cancer Institute β Clovis, California
B Cell Precursor Acute Lymphoblastic Leukemia
View Study & Checklist βPhase II Study of the Combination of Subcutaneous Blinatumomab and Olverembatinib in Patients With Philadelphia Chromosome (ph)-Positive and/or BCR::ABL1 Positive Acute Lymphoblastic Leukemia (ALL)
π MD Anderson Cancer Center β Houston, Texas
Phase II Clinical Trial
View Study & Checklist βA Phase IB Trial of Subcutaneous Blinatumomab in Combination With Revumenib for Patients With KMT2A-rearranged Acute Lymphoblastic Leukemia
π MD Anderson Cancer β Houston, Texas
Blinatumomab
View Study & Checklist βPhase 1/2 FLAG-IDA, VEN and Asciminib in CML and Ph+ AML
π UT MD Anderson β Houston, Texas
Myeloid Leukemia
View Study & Checklist βPhase 2 Study to Assess the Safety and Efficacy of Subcutaneous Blinatumomab in Patients With Measurable Residual Disease Positive B-cell Acute Lymphoblastic Leukemia
π MD Anderson Cancer Center β Houston, Texas
Phase 2 Study
View Study & Checklist βA Study of Inotuzumab and Blinatumomab in People With B-cell Acute Lymphoblastic Leukemia
π Memorial Sloan Kettering Cancer Center (All Protocol Activities) β New York, New York
B-cell Acute Lymphoblastic Leukemia
View Study & Checklist βTCRΞ±Ξ²-depleted Progenitor Cell Graft With Early Memory T-cell DLI, Plus Selected Use of Blinatumomab, in naΓ―ve T-cell Depleted Haploidentical Donor Hematopoietic Cell Transplantation for Hematologic Malignancies
π St. Jude Children's Research Hospital β Memphis, Tennessee
Hematologic Malignancy
View Study & Checklist βTherapy for Newly Diagnosed Patients With B-Cell Precursor Acute Lymphoblastic Leukemia and Lymphoma
π Novant Health Presbyterian Hemby Children's Hospital β Charlotte, North Carolina
Acute Lymphoblastic Leukemia
View Study & Checklist βCApivasertib, Venetoclax And Low-intensity chemotheRapY for Adults With ALL/LBL
π University of Chicago Medicine Comprehensive Cancer Center β Chicago, Illinois
Leukemia
View Study & Checklist βTINI 2: Total Therapy for Infants With Acute Lymphoblastic Leukemia II
π Phoenix Children's Hospital β Phoenix, Arizona
Lymphoblastic Leukemia
View Study & Checklist βBlinatumomab After TCR Alpha Beta/CD19 Depleted HCT
π Children's Hospital of Wisconsin β Milwaukee, Wisconsin
B-cell Acute Lymphoblastic Leukemia
View Study & Checklist βStudy of Pedi-cRIB: Mini-Hyper-CVD With Condensed Rituximab, Inotuzumab Ozogamicin and Blinatumomab (cRIB) for Relapsed Therapy for Pediatric With B-Cell Lineage Acute Lymphocytic Leukemia
π M D Anderson Cancer Center β Houston, Texas
Leukemia
View Study & Checklist βInotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy
π Children's Hospital of Alabama β Birmingham, Alabama
B Acute Lymphoblastic Leukemia
View Study & Checklist βPhase Ib/II Study Assessing the Clinical Activity and Safety of Brexucabtagene Autoleucel as a Consolidation in Patients With Relapsed/Refractory (R/R) and Newly Diagnosed B-cell Acute Lymphocytic Leukemia (ALL) Post Cytoreduction With Mini-HCVD-inotuzumab-blinatumomab/HCVAD-inotuzumab-blinatumomab
π MD Anderson Cancer Center β Houston, Texas
Relapsed/Refractory
View Study & Checklist βIntrathecal Chemoprophylaxis to Prevent Neurotoxicity Associated With Blinatumomab Therapy for Acute Lymphoblastic Leukemia
π Northside Hospital β Atlanta, Georgia
Acute Lymphoblastic Leukemia
View Study & Checklist βPhase I/II Study of the Combination of Blinatumomab and Asciminib in Patients With Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia
π Montefiore Einstein Comprehensive Cancer Center β The Bronx, New York
Philadelphia Chromosome-Positive
View Study & Checklist βA Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL)
π Children's Hospital of Alabama β Birmingham, Alabama
Down Syndrome
View Study & Checklist βRecombinant Erwinia Asparaginase and Venetoclax in Combination With Blinatumomab for the Treatment of Relapsed or Refractory CD19 Positive B-cell Acute Lymphoblastic Leukemia
π City of Hope Medical Center β Duarte, California
Recurrent B Acute Lymphoblastic Leukemia
View Study & Checklist βInotuzumab Ozogamicin and Combination Chemotherapy in Treating Patients With Acute Lymphoblastic Leukemia
π M D Anderson Cancer Center β Houston, Texas
B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1
View Study & Checklist βBlinatumomab, Methotrexate, Cytarabine, and Ponatinib in Treating Patients With Philadelphia Chromosome-Positive, or BCR-ABL Positive, or Relapsed/Refractory, Acute Lymphoblastic Leukemia
π M D Anderson Cancer Center β Houston, Texas
Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive
View Study & Checklist βABL001 + Dasatinib + Prednisone + Blinatumomab in BCR-ABL+ B-ALL or CML
π University of Chicago Comprehensive Cancer Center β Chicago, Illinois
B-cell Acute Lymphoblastic Leukemia
View Study & Checklist βA Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL)
π Children's Hospital of Alabama β Birmingham, Alabama
B Acute Lymphoblastic Leukemia
View Study & Checklist βBlinatumomab, Inotuzumab Ozogamicin, and Combination Chemotherapy as Frontline Therapy in Treating Patients With B Acute Lymphoblastic Leukemia
π M D Anderson Cancer Center β Houston, Texas
B Acute Lymphoblastic Leukemia
View Study & Checklist βInotuzumab Ozogamicin and Blinatumomab With or Without Ponatinib in Treating Patients With Newly Diagnosed, Recurrent, or Refractory CD22-Positive B-Lineage Acute Lymphoblastic Leukemia
π University of Alabama at Birmingham Cancer Center β Birmingham, Alabama
B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative
View Study & Checklist βA Phase 2 Master Protocol Assessing Inebilizumab and Blinatumomab in Autoimmune Diseases
π HonorHealth Research and Innovation Institute β Scottsdale, Arizona
Systemic Lupus Erythematosus
View Study & Checklist βALL Backbone in AYAs
π Dana Farber Cancer Institute β Boston, Massachusetts
Acute Lymphoblastic Leukemia
View Study & Checklist βTesting the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia
π Children's Hospital of Alabama β Birmingham, Alabama
Acute Leukemia of Ambiguous Lineage
View Study & Checklist βStudy of HQP1351 in Subjects With Refractory CML and Ph+ ALL
π University of Alabama at Birmingham β Birmingham, Alabama
Leukemia, Myeloid, Chronic
View Study & Checklist β